Shilpa Medicare gets DCGI approval for ‘2-Deoxy2-Glucose’
31st Aug 2021

Shilpa Medicare has received Drugs Controller General of India (DCGI) approval for ‘2-Deoxy2-Glucose’ (Bulk & Oral Powder). The bulk is manufactured by Shilpa Medicare, API facility in Raichur,' Karnataka. The Oral Powder is manufactured by its subsidiary, Shilpa Therapeutics, facility in Hyderabad, Telangana. 2-Deoxy-2-Glucose Oral Powder is approved for the treatment of adjunct therapy in moderate to severe COVID-19 patients. The product will be available with a brand name '2-DGSHIL'.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.